101419-79-8 Usage
Explanation
The chemical name of the compound, which describes its structure.
Explanation
The common name or alias for the compound, which is used more casually in conversation and literature.
Explanation
The chemical formula representing the number of atoms of each element in the compound (carbon, hydrogen, chlorine, nitrogen, and oxygen).
Explanation
Indicates that the compound is primarily composed of carbon atoms and is derived from living organisms or their byproducts.
Explanation
Shows that the compound is derived from pyridinecarboxylic acid, which is a type of organic compound.
Explanation
One of the functional groups present in the compound, which is a phenyl ring with a chlorine atom attached.
Explanation
The primary use of the compound, which is to treat bacterial infections by targeting a wide range of bacteria.
Explanation
How the antibiotic works, by preventing bacteria from growing and damaging their protective cell walls, ultimately leading to their death.
Explanation
Indicates that the compound is generally well-tolerated and has been proven to be effective in treating various bacterial infections.
Type of compound
Organic compound
Derivative
Pyridinecarboxylic acid derivative
Contains
Chlorophenyl group
Function
Broad-spectrum antibiotic
Mechanism of action
Inhibits bacterial growth and disrupts cell walls
Safety and efficacy
Considered safe and effective
Check Digit Verification of cas no
The CAS Registry Mumber 101419-79-8 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,0,1,4,1 and 9 respectively; the second part has 2 digits, 7 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 101419-79:
(8*1)+(7*0)+(6*1)+(5*4)+(4*1)+(3*9)+(2*7)+(1*9)=88
88 % 10 = 8
So 101419-79-8 is a valid CAS Registry Number.
101419-79-8Relevant articles and documents
SUBSTITUTED HYDANTOINAMIDES AS ADAMTS7 ANTAGONISTS
-
Page/Page column 192, (2021/05/21)
The application relates to substituted hydantoinamides of formula (I) as ADAMTS7 antagonists, to processes for their preparation, their use alone or in combination for the treatment or prophylaxis of diseases, in particular of cardiovascular diseases, including atherosclerosis, coronary artery disease (CAD), peripheral vascular disease (PAD), arterial occlusive disease or restenosis after angioplasty. R1 is hydrogen, alkyl, cycloalkyl, heterocycloalkyl, heteroaryl or phenyl; R2 is hydrogen, cyano, halogen, alkylsulfonyl, alkyl, cycloalkyl or alkoxy; R3, R4, R5, R6, R7 and R8 are independently hydrogen, halogen, alkyl or alkoxy; most groups being optionally substituted; with the proviso that at least one of R2, R3, R4 is H; X1, X2, X3, X4, X5 and X6 are independently N or C; with the proviso that in each ring maximal one X is N.
